At the heart of drug
design is the discovery of molecules that
bind with high affinity to their drug targets. Biotin forms the strongest
known noncovalent ligand–protein interactions with avidin and
streptavidin, achieving femtomolar and picomolar affinities, respectively.
This is made even more exceptional because biotin achieves this with
a meagre molecular weight of 240 Da. Surprisingly, the approaches
by which biotin achieves this are not in the standard repertoire of
current medicinal chemistry practice. Biotin’s biggest lesson
is the importance of nonclassical H-bonds in protein–ligand
complexes. Most of biotin’s affinity stems from its flexible
valeric acid side chain that forms CH−π, CH–O,
and classical H-bonds with the lipophilic region of the binding pocket.
Biotin also utilizes an oxyanion hole, a sulfur-centered H-bond, and
water solvation in the bound state to achieve its potency. The facets
and advantages of biotin’s approach to binding should be more
widely adopted in drug design.